• Je něco špatně v tomto záznamu ?

The costimulatory signal CD28 is fully functional but cannot correct the impaired antigen response in T cells of patients with common variable immunodeficiency

MB Fischer, HM Wolf, H Eggenbauer, V Thon, E Vogel, J Lokaj, J Litzman, JW Mannhalter, MM Eibl

. 1994 ; 95 (2) : 209-214.

Jazyk angličtina Země Anglie, Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc13036490

Grantová podpora
IZ1409 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje Online Plný text

NLK Free Medical Journals od 1966 do Před 1 rokem
PubMed Central od 1966 do Před 1 rokem
Medline Complete (EBSCOhost) od 1966-01-01 do Před 1 rokem
Wiley Online Library (archiv) od 1990-01-01 do 2012-12-31

Odkazy

PubMed 8306493
Knihovny.cz E-zdroje

A wide spectrum of different immunologic abnormalities have been postulated as being responsible for the impairment of specific antibody production and the decrease in all or selected immunoglobulin isotypes present in common variable immunodeficiency (CVID). These abnormalities include impaired B cell differentiation and/or function, defective macrophage function, and significant T cell defects. The aim of the present study was to delineate whether the accessory molecule CD28 is involved in the impaired antigen response of T cells from patients with CVID. Our results demonstrate that CD28 costimulation was functional in T cells stimulated with anti-CD3 or anti-TCR MoAb, but could not correct the impaired response of patients' peripheral blood T cells to tetanus toxoid. Analysis of patients' long-term cultured T cells further confirmed these results. Exogenous rIL-2, another costimulus, augmented but did not correct the defective proliferation and lymphokine production in patients' antigen-driven peripheral blood T lymphocytes or in long-term cultured T cells. These findings indicate that the CD28 signalling pathway in these patients' T cells is unimpaired, and that costimulation via CD28 cannot correct the defect occurring in the course of TCR-mediated T cell activation.

000      
00000naa a2200000 a 4500
001      
bmc13036490
003      
CZ-PrNML
005      
20131125085310.0
007      
ta
008      
131114s1994 enk f 000 0|eng||
009      
AR
035    __
$a (PubMed)8306493
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fischer, M.B. $u Institute of Immunology, University of Vienna, Austria.
245    14
$a The costimulatory signal CD28 is fully functional but cannot correct the impaired antigen response in T cells of patients with common variable immunodeficiency / $c MB Fischer, HM Wolf, H Eggenbauer, V Thon, E Vogel, J Lokaj, J Litzman, JW Mannhalter, MM Eibl
520    9_
$a A wide spectrum of different immunologic abnormalities have been postulated as being responsible for the impairment of specific antibody production and the decrease in all or selected immunoglobulin isotypes present in common variable immunodeficiency (CVID). These abnormalities include impaired B cell differentiation and/or function, defective macrophage function, and significant T cell defects. The aim of the present study was to delineate whether the accessory molecule CD28 is involved in the impaired antigen response of T cells from patients with CVID. Our results demonstrate that CD28 costimulation was functional in T cells stimulated with anti-CD3 or anti-TCR MoAb, but could not correct the impaired response of patients' peripheral blood T cells to tetanus toxoid. Analysis of patients' long-term cultured T cells further confirmed these results. Exogenous rIL-2, another costimulus, augmented but did not correct the defective proliferation and lymphokine production in patients' antigen-driven peripheral blood T lymphocytes or in long-term cultured T cells. These findings indicate that the CD28 signalling pathway in these patients' T cells is unimpaired, and that costimulation via CD28 cannot correct the defect occurring in the course of TCR-mediated T cell activation.
590    __
$a bohemika - dle Pubmed
650    02
$a mladiství $7 D000293
650    02
$a dospělí $7 D000328
650    02
$a monoklonální protilátky $x imunologie $7 D000911
650    12
$a antigeny CD28 $x fyziologie $7 D018106
650    12
$a běžná variabilní imunodeficience $x imunologie $7 D017074
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a interleukin-2 $x biosyntéza $x farmakologie $7 D007376
650    12
$a aktivace lymfocytů $7 D008213
650    02
$a mužské pohlaví $7 D008297
650    02
$a lidé středního věku $7 D008875
650    12
$a T-lymfocyty $x imunologie $7 D013601
700    1_
$a Wolf, H.M. $u Institute of Immunology, University of Vienna, Austria.
700    1_
$a Eggenbauer, H. $u Institute of Immunology, University of Vienna, Austria.
700    1_
$a Thon, Vojtěch $u Institute of Immunology, University of Vienna, Austria. $7 xx0060109
700    1_
$a Vogel, E. $u Institute of Immunology, University of Vienna, Austria.
700    1_
$a Lokaj, Jindřich, $d 1939- $7 jk01072349 $u Institute of Clinical Immunology, Masaryk University, Brno, Czech Republic
700    1_
$a Litzman, Jiří, $7 xx0000488 $u Institute of Clinical Immunology, Masaryk University, Brno, Czech Republic $d 1958-
700    1_
$a Mannhalter, J.W. $u Institute of Immunology, University of Vienna, Austria
700    1_
$a Eibl, M.M. $u Immuno AG, Vienna, Austria
773    0_
$t Clinical and experimental immunology $x 0009-9104 $g Roč. 95, č. 2 (1994), s. 209-214 $p Clin Exp Immunol $w MED00009471
910    __
$a ABA008 $b B 1308 $y 4 $z 0
990    __
$a 20131114141023 $b ABA008
991    __
$a 20131125085943 $b ABA008
999    __
$a ok $b bmc $g 1000796 $s 834975
BAS    __
$a 3
BMC    __
$a 1994 $b 95 $c 2 $d 209-214 $x MED00009471 $i 0009-9104 $m Clinical and experimental immunology $n Clin Exp Immunol
GRA    __
$a IZ1409 $p MZ0
LZP    __
$a NLK 2013-11/lpbo

Najít záznam

Citační ukazatele

Možnosti archivace